Antibody Drug Conjugate Market Analysis, Size, Share, and Forecast 2031
The Antibody Drug Conjugate Market in 2023 is US$ 10.50 billion, and is expected to reach US$ around 35 billion by 2031 at a CAGR of 19.6%.
FutureWise Research published a report that analyzes Antibody Drug Conjugate Market trends to predict the market’s growth. The report begins with a description of the business environment and explains the commercial summary of the chain structure. Based on the market trends and driving factors presented in the report, clients will be able to plan the roadmap for their products and services taking into account various socio-economic factors.
Additionally, it illustrates the corporate profiles and situation of competitive landscape amongst numerous associated corporations including the analysis of market evaluation and options associated with the worth chain. This Antibody Drug Conjugate research report provides insights on market overview, market segmentation, current and future pricing, growth analysis, competitive landscape and other such premium insights within the forecast period.
Request a Sample Report @ Request for Antibody Drug Conjugate Market Sample
Antibody Drug Conjugate Market Segmentation:
By Type
- Monoclonal Antibodies
- Linker
- Drug/Toxin
- Others
By Application
- Leukemia
- Acute Myeloid Leukemia (AML)
- Chronic Myeloid Leukemia (CML)
- Acute Lymphocytic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
- Prostate Cancer
- Kidney Cancer
- Pancreas Cancer
- Ovary Cancer
- Glioblastoma
- Lung Cancer
- Colon Cancer
- Breast Cancer
- Skin Cancer
- Solid Tumors
- Multiple Myeloma
- Lymphoma
By Product
- Adcetris
- Kadcyla
- Others
By Technology
- ImmunoGen Technology
- Seattle Genetics Technology
- Immunomedics Technology
- Others
By End User
- Hospitals
- Specialized Cancer Centers
- Academic Research Institutes
- Biopharmaceutical Companies
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Major players included in the Antibody Drug Conjugate Market:
- Seattle Genetics
- ImmunoGen, Inc.
- Roche Holding AG
- Genentech
- Concortis Biotherapeutics
- AGENSYS, INC.
- Antikor
- Immunomedics
- Pfizer Inc.
- Celldex Therapeutics
- Millennium Pharmaceuticals
- AbbVie Inc.
- Bayer HealthCare
- Astellas Pharma/Agensys
- Progenics Pharmaceuticals
- Mersana Therapeutics
- Synthon
- Heidelberg Pharma
- Oxford BioTherapeutics
Please visit full report of the Antibody Drug Conjugate market @ Visit Antibody Drug Conjugate Market
Competitive Landscape:
- Tier one players – market players with a significant share of the market
- Tier two players
- Players with rapid growth
- New Entries
FutureWise Key Takeaways:
- Prospects for growth
- Analysis of SWOT
- Key trends
- Key Data-points affecting market growth
Objectives of the Study:
- To provide report with an in-depth analysis of the Antibody Drug Conjugate Market By Type, By Application, By Product, By Technology, By End User and By Region
- To offer data-points and comprehensive data on factors affecting the market (Opportunities, drivers, and industry-specific restraints)
- Analysis and forecasting of micro-markets, as well as the scope of the market.
- To predict the size and share, market forecast, in key regions — North America, Europe, Asia Pacific, and rest of the world
- To record and evaluate competition -mergers and expansions, product launches, and technological advancements within the market
Flexible Delivery Model:
- With our flexible delivery model, you will be able to suggest changes within the scope/table of content based on your requirement.
- Customization services are included with the purchase of any license type of report.
- Customization requests can be sent directly to: sales@futurewiseresearch.com
FutureWise Research:
Contact Person: Vinay T.
Email: sales@futurewiseresearch.com
Contact Number: UK: +44 1416289353 | US: +1 3477094931
Website: www.futurewiseresearch.com
